Sign In
Buy TCRT
$2.62
-0.130 (-4.73%)
At Close: Jun 03, 2026
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
11:01am, Tuesday, 26'th May 2026
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, a
FORT LAUDERDALE, Fla., May 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evalua
Valion Bio Appoints Melinda Lackey as General Counsel
04:05pm, Monday, 04'th May 2026
/PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod for
Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop
11:47am, Monday, 02'nd Mar 2026
Alaunos Therapeutics Inc. (NASDAQ: TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003.
Alaunos' ALN1003 shows dose dependent weight loss, better body composition, reduced liver weight, and improved liver biomarkers in preclinical studies.
Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Drops By 14.6%
01:40am, Thursday, 19'th Feb 2026
Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 44,597 shares, a decline of 14
Alaunos Therapeutics (NASDAQ:TCRT) Trading 3.1% Higher – What’s Next?
03:33am, Thursday, 22'nd Jan 2026
Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) was up 3.1% during mid-day trading on Wednesday. The company traded as high as $3.00 and last traded at $3.00. Approximately 16,982 shares c
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
08:00am, Monday, 23'rd Jun 2025
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “
NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today issued a public statement urging A
NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital,” “we,” “our,” or “us”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), today a
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
07:57am, Monday, 18'th Dec 2023
Alaunos Therapeutics (NASDAQ: TCRT ) stock is up on Monday despite a lack of news from the clinical-stage oncology-focused cell therapy company. There are no new press releases or filings with the Se
Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
07:56am, Tuesday, 14'th Nov 2023
Alaunos Therapeutics (NASDAQ: TCRT ) stock is heading higher on Tuesday following the release of the clinical-stage oncology-focused cell therapy company's Q3 earnings report. The Alaunos Therapeutic
HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
11:44am, Wednesday, 16'th Aug 2023
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the second quarter ended June 30, 2023.
